drugset / Trial / NCT00066365

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

NCT00066365 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the growth of tumor cells and shrink the tumor so that it can be removed during surgery. Sargramostim may then kill any tumor cells remaining after surgery. This may be an effective treatment for osteosarcoma that has spread to the lung. PURPOSE: This phase II trial is studying how well inhaled sargramostim works in treating patients who are undergoing surgery for the first recurrence of osteosarcoma that has spread to the lung.

Timeline

Start
2004-07
Primary completion
2010-07
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic 240 ug Inhaled
Subject sargramostim Protein / enzyme biologic 1000 ug Inhaled
Subject sargramostim Protein / enzyme biologic 1750 ug Inhaled